Home › Compare › CSBTF vs VICI

CSBTF vs VICI: Dividend Comparison 2026

CSBTF yields 7.18% · VICI yields 5.88%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSBTF wins by $1.8K in total portfolio value
10 years
CSBTF
CSBTF
● Live price
7.18%
Share price
$27.85
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.2K
Annual income
$1,132.80
Full CSBTF calculator →
VICI
VICI Properties Inc.
● Live price
5.88%
Share price
$28.90
Annual div
$1.70
5Y div CAGR
8.1%
Payout ratio
74%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$2,376.06
Full VICI calculator →

Portfolio growth — CSBTF vs VICI

📍 CSBTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSBTFVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSBTF + VICI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CSBTF pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSBTF
Annual income on $10K today (after 15% tax)
$610.41/yr
After 10yr DRIP, annual income (after tax)
$962.88/yr
VICI
Annual income on $10K today (after 15% tax)
$500.00/yr
After 10yr DRIP, annual income (after tax)
$2,019.65/yr
At 15% tax rate, VICI beats the other by $1,056.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSBTF + VICI for your $10,000?

CSBTF: 50%VICI: 50%
100% VICI50/50100% CSBTF
Portfolio after 10yr
$31.3K
Annual income
$1,754.43/yr
Blended yield
5.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

CSBTF
No analyst data
Altman Z
15.0
Piotroski
4/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+9.3% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSBTF buys
0
VICI buys
0
No recent congressional trades found for CSBTF or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSBTFVICI
Forward yield7.18% ✓5.88%
Annual dividend / share$2.00 ✓$1.70
Payout ratio50% ✓74%
1-year div growth0%6.3% ✓
5-year div CAGR0%8.1% ✓
Portfolio after 10y$32.2K ✓$30.3K
Annual income after 10y$1,132.80$2,376.06 ✓
Total dividends collected$9.3K$13.2K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CSBTF vs VICI ($10,000, DRIP)

YearCSBTF PortfolioCSBTF Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$11,418$718.13$11,056$635.88+$362.00 → CSBTF
2$12,984$766.33$12,250$729.34+$734.00 → CSBTF
3$14,707$814.40$13,602$838.33+$1.1K → CSBTF
4$16,599$862.14$15,139$965.75+$1.5K → CSBTF
5$18,670$909.37$16,890$1,115.11+$1.8K → CSBTF
6$20,933$955.93$18,890$1,290.64+$2.0K → CSBTF
7$23,400$1,001.68$21,181$1,497.50+$2.2K → CSBTF
8$26,084$1,046.47$23,813$1,741.95+$2.3K → CSBTF
9$29,000$1,090.21$26,845$2,031.67+$2.2K → CSBTF
10$32,163$1,132.80$30,348$2,376.06+$1.8K → CSBTF

CSBTF vs VICI: Complete Analysis 2026

CSBTF — Stock

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

Full CSBTF Calculator →

VICI — REIT

VICI Properties is a gaming and entertainment REIT owning properties including Caesars Palace and MGM Grand in Las Vegas. Its triple-net leases with leading casino operators provide highly predictable income. VICI has grown its dividend 8%+ annually since its 2018 IPO, making it one of the fastest-growing REITs.

Full VICI Calculator →
📬

Get this CSBTF vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSBTF vs SCHDCSBTF vs JEPICSBTF vs OCSBTF vs KOCSBTF vs MAINCSBTF vs NNNCSBTF vs EPRTCSBTF vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.